Scientists found new small molecules. These molecules stop certain proteins called beta-arrestins from working.

科學家發現了新型小分子。這些分子能阻止被稱為 beta-arrestins 的特定蛋白質運作。

Beta-arrestins help cells send signals. Before this, scientists could not stop these proteins with medicine. Now, they found three new chemicals. These chemicals stop the proteins but do not stop other important cell signals.

Beta-arrestins 負責幫助細胞傳遞訊號。在此之前，科學家無法使用藥物來阻止這些蛋白質。現在，他們發現了三種新型化學物質。這些化學物質能阻止蛋白質，但不會影響其他重要的細胞訊號。

One chemical is called Cmpd-5. It fits into a small hole in the protein. This changes the shape of the protein. Because the shape changes, the protein cannot connect to other parts of the cell.

其中一種化學物質稱為 Cmpd-5。它會嵌入蛋白質的一個小孔中。這會改變蛋白質的形狀。由於形狀改變，蛋白質便無法與細胞的其他部分連接。

This discovery is important for health. It can help doctors treat asthma. It can also help with heart problems and sugar problems in the body.

這項發現對健康至關重要。它能幫助醫生治療哮喘，也能協助處理心臟問題以及體內的血糖問題。

These new chemicals help scientists understand proteins better. They can use them to make new medicines.

這些新型化學物質幫助科學家更深入地了解蛋白質，並可用於研發新藥。

Researchers have created the first small-molecule inhibitors that can directly target β-arrestins. These are specific proteins that control how G-protein-coupled receptors (GPCRs) send signals and move within a cell.

研究人員開發出了首批能直接針對 β-arrestins 的小分子抑制劑。這些是控制 G 蛋白耦合受體 (GPCRs) 在細胞內如何傳遞信號及移動的特定蛋白質。

In the past, scientists could only study β-arrestins using genetic models because they lacked the right chemical tools. However, this new study used a detailed screening process to find three specific modulators: Cmpd-5, Cmpd-46, and Cmpd-64. These molecules can stop β-arrestins from connecting with activated receptors. Importantly, they do this without affecting G-protein coupling, which means the cell can still produce essential responses like calcium mobilization.

過去，由於缺乏合適的化學工具，科學家只能使用基因模型來研究 β-arrestins。然而，這項新研究透過詳細的篩選過程，發現了三種特定的調節劑：Cmpd-5、Cmpd-46 與 Cmpd-64。這些分子能阻止 β-arrestins 與活化的受體結合。重要的是，它們在執行此操作時不會影響 G 蛋白耦合，這意味著細胞仍能產生如鈣離子動員等必要的反應。

Using advanced imaging and computer simulations, the team discovered that Cmpd-5 binds to a previously unknown area called the MCL site. When Cmpd-5 binds, it changes the shape of the protein, making it impossible for the protein to connect fully with the receptor. Consequently, this prevents several downstream biological processes, such as the movement of T-cells and the contraction of heart muscle cells.

利用先進的成像技術與電腦模擬，研究團隊發現 Cmpd-5 會結合在一個先前未知的區域，稱為 MCL 位點。當 Cmpd-5 結合時，會改變蛋白質的形狀，使得蛋白質無法與受體完全結合。因此，這會阻止多項下游生物過程，例如 T 細胞的移動與心肌細胞的收縮。

Experts emphasize that this discovery allows medicine to move from focusing only on receptors to targeting the proteins inside the cell. This approach could lead to new treatments for diseases where receptor behavior is problematic, such as asthma or metabolic issues related to the GLP-1 receptor.

專家強調，這項發現使得醫學能從僅關注受體，轉向針對細胞內的蛋白質。這種方法可為受體行為出現問題的疾病提供新治療方法，例如氣喘或與 GLP-1 受體相關的代謝問題。

The discovery of these inhibitors creates a new way to regulate β-arrestins and provides a useful tool for developing precise medical treatments.

這些抑制劑的發現創造了一種調節 β-arrestins 的新方法，並為開發精準醫療治療提供了有用的工具。

Researchers have developed the first small-molecule inhibitors capable of directly targeting β-arrestins, proteins that regulate G-protein-coupled receptor (GPCR) signaling and trafficking.

研究人員開發了首批能夠直接針對 β-arrestins 的小分子抑制劑，這些蛋白質負責調節 G 蛋白偶聯受體 (GPCR) 的信號傳導與轉運。

Historically, the modulation of β-arrestins—essential scaffolds for GPCR desensitization and internalization—has been restricted to genetic models due to a lack of direct pharmacological tools. The current study utilized a multi-tiered discovery pipeline, incorporating differential scanning fluorimetry and functional screens, to identify three distinct modulators: Cmpd-5, Cmpd-46, and Cmpd-64. These agents demonstrate the capacity to disrupt the engagement between β-arrestins and agonist-activated receptors without perturbing G-protein coupling, thereby sustaining second messenger responses such as cAMP accumulation and calcium mobilization.

在過去，由於缺乏直接的藥理工具，對 β-arrestins（GPCR 去敏感化與內吞的關鍵支架）的調節一直僅限於基因模型。本研究利用多層次的開發管線，結合差示掃描螢光法與功能篩選，鑑定出三種不同的調節劑：Cmpd-5、Cmpd-46 與 Cmpd-64。這些藥劑能在不干擾 G 蛋白偶聯的情況下，阻斷 β-arrestins 與激動劑激活受體之間的結合，從而維持如 cAMP 累積與鈣離子動員等第二信使反應。

Mechanistic characterization via cryo-electron microscopy and molecular dynamics simulations revealed that Cmpd-5 occupies a previously uncharacterized allosteric pocket, designated as the MCL site. This site is composed of the middle, C, and lariat loops of β-arrestin1. The binding of Cmpd-5 induces a conformational rearrangement—specifically a modest interdomain rotation of approximately 8° and inward bending of the middle loop—which renders the protein incompatible with full receptor engagement. This structural stabilization effectively inhibits β-arrestin-dependent downstream signaling, including ERK1/2 activation, T-cell chemotaxis, and cardiomyocyte contractility.

透過低溫電子顯微鏡與分子動力學模擬的機制分析顯示，Cmpd-5 佔據了一個先前未被定義的別構口袋，被命名為 MCL 位點。此位點由 β-arrestin1 的中段環 (middle loop)、C 環與套索環 (lariat loop) 組成。Cmpd-5 的結合會誘導構象重排——具體為約 8° 的輕微域間旋轉以及中段環的向內彎曲——使得蛋白質無法與受體完全結合。這種結構穩定化有效地抑制了 β-arrestin 依賴性的下游信號傳導，包括 ERK1/2 激活、T 細胞趨化作用與心肌細胞收縮力。

Stakeholder positioning suggests that this discovery facilitates a transition from receptor-centric pharmacology to the direct modulation of intracellular transducers. The ability to selectively uncouple β-arrestins from receptors provides a theoretical framework for treating pathologies where receptor desensitization is maladaptive, such as airway hyperresponsiveness in asthma or metabolic dysfunction associated with the GLP-1 receptor.

相關持份者的定位指出，此發現促進了藥理學從「以受體為中心」轉向「直接調節細胞內轉導子」。能夠選擇性地將 β-arrestins 與受體解耦，為治療受體去敏感化適應不良的病理提供了理論框架，例如哮喘中的氣道高反應性，或與 GLP-1 受體相關的代謝功能障礙。

The identification of these inhibitors establishes a new mechanistic framework for the allosteric regulation of β-arrestins and provides chemical probes for pathway-specific GPCR therapeutics.

鑑定出這些抑制劑建立了一個 β-arrestins 別構調節的新機制框架，並為路徑特異性的 GPCR 治療提供了化學探針。